Filip Machaj

1.8k total citations · 1 hit paper
25 papers, 1.2k citations indexed

About

Filip Machaj is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Neurology. According to data from OpenAlex, Filip Machaj has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Cardiology and Cardiovascular Medicine and 4 papers in Neurology. Recurrent topics in Filip Machaj's work include Rheumatoid Arthritis Research and Therapies (4 papers), Long-Term Effects of COVID-19 (4 papers) and COVID-19 Clinical Research Studies (3 papers). Filip Machaj is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (4 papers), Long-Term Effects of COVID-19 (4 papers) and COVID-19 Clinical Research Studies (3 papers). Filip Machaj collaborates with scholars based in Poland, Canada and Iran. Filip Machaj's co-authors include Jakub Rosik, Bartosz Szostak, Saeid Ghavami, Marek Łoś, Sylwester Drożdżal, Katarzyna Kotfis, Kacper Lechowicz, Andrzej Pawlik, Tayyebeh Madrakian and Shayan Amiri and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Filip Machaj

24 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

2021 180 citations Sylwester Drożdżal, Jakub Rosik et al. Drug Resistance Updates profile →

Peers

Filip Machaj

NEURO

SURGE

Jakub Rosik Poland

Τaxiarchis Κonstantinos Νikolouzakis Greece

Negin Parsamanesh Iran

Wenbin Tan United States

Shenghao Tu China

Kai Meng China

Mohamed El‐Mesery Egypt

Ting Zhu China

Dayong Cai China

Jakub Rosik Poland

Filip Machaj

445 ×1.0

324 ×1.1

176 ×1.0

161 ×1.1

NEURO

149 ×1.1

SURGE

Citations per year, relative to Filip Machaj Filip Machaj (= 1×) peers Jakub Rosik

Countries citing papers authored by Filip Machaj

Since Specialization

Citations

This map shows the geographic impact of Filip Machaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip Machaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip Machaj more than expected).

Fields of papers citing papers by Filip Machaj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip Machaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip Machaj. The network helps show where Filip Machaj may publish in the future.

Co-authorship network of co-authors of Filip Machaj

This figure shows the co-authorship network connecting the top 25 collaborators of Filip Machaj. A scholar is included among the top collaborators of Filip Machaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip Machaj. Filip Machaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orczykowski, Michał, Marcin Kowalski, Filip Machaj, et al.. (2025). Radiofrequency Versus Cryoballoon 180‐Day Mortality Risk After Atrial Fibrillation Ablation: An 8‐Year Analysis. Pacing and Clinical Electrophysiology. 48(3). 363–366.

Machaj, Filip, et al.. (2025). microRNAs as Biomarkers and Therapeutic Targets in Rheumatoid Arthritis. International Journal of Molecular Sciences. 26(20). 9950–9950. 1 indexed citations

Machaj, Filip, Dominik Strapagiel, Marta Sobalska‐Kwapis, et al.. (2023). Analytical sensitivity of a method is critical in detection of low-level BRCA1 constitutional epimutation. Scientific Reports. 13(1). 16102–16102. 2 indexed citations

Machaj, Filip, Jakub Rosik, Bartosz Szostak, et al.. (2023). The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis. Clinical Rheumatology. 42(9). 2477–2483. 1 indexed citations

Rosik, Jakub, et al.. (2023). Improving mitochondrial function in preclinical models of heart failure: therapeutic targets for future clinical therapies?. Expert Opinion on Therapeutic Targets. 27(7). 593–608. 3 indexed citations

Aghaei, Mahmoud, Marveh Rahmati, Filip Machaj, et al.. (2021). The Role of BiP and the IRE1α–XBP1 Axis in Rhabdomyosarcoma Pathology. Cancers. 13(19). 4927–4927. 11 indexed citations

Kotowski, Krzysztof, Jakub Rosik, Filip Machaj, et al.. (2021). Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets. Cancers. 13(4). 909–909. 96 indexed citations

Drożdżal, Sylwester, Jakub Rosik, Kacper Lechowicz, et al.. (2021). An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resistance Updates. 59. 100794–100794. 180 indexed citations breakdown →

Rosik, Jakub, Bartosz Szostak, Filip Machaj, & Andrzej Pawlik. (2021). The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation. International Journal of Molecular Sciences. 22(6). 3081–3081. 4 indexed citations

10.

Ahmadi, Mazaher, Shayan Amiri, Stevan Pecic, et al.. (2020). Pleiotropic effects of statins: A focus on cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1866(12). 165968–165968. 114 indexed citations

11.

Drożdżal, Sylwester, Jakub Rosik, Kacper Lechowicz, et al.. (2020). FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates. 53. 100719–100719. 126 indexed citations

12.

Hybiak, Jolanta, Filip Machaj, Jakub Rosik, et al.. (2020). Reprogramming and transdifferentiation - two key processes for regenerative medicine. European Journal of Pharmacology. 882. 173202–173202. 13 indexed citations

13.

Szostak, Bartosz, Filip Machaj, Jakub Rosik, & Andrzej Pawlik. (2020). Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients. Expert Opinion on Drug Metabolism & Toxicology. 16(7). 617–626. 26 indexed citations

14.

Drożdżal, Sylwester, Jakub Rosik, Kacper Lechowicz, et al.. (2020). COVID-19: Pain Management in Patients with SARS-CoV-2 Infection—Molecular Mechanisms, Challenges, and Perspectives. Brain Sciences. 10(7). 465–465. 47 indexed citations

15.

Machaj, Filip, et al.. (2019). New therapies for the treatment of heart failure: a summary of recent accomplishments. SHILAP Revista de lepidopterología. 5 indexed citations

16.

Machaj, Filip, et al.. (2019). <p>New therapies for the treatment of heart failure: a summary of recent accomplishments</p>. Therapeutics and Clinical Risk Management. Volume 15. 147–155. 28 indexed citations

17.

Hybiak, Jolanta, et al.. (2019). Aspirin and its pleiotropic application. European Journal of Pharmacology. 866. 172762–172762. 84 indexed citations

18.

Amiri, Shayan, Sanaz Dastghaib, Mazaher Ahmadi, et al.. (2019). Betulin and its derivatives as novel compounds with different pharmacological effects. Biotechnology Advances. 38. 107409–107409. 198 indexed citations

19.

Szostak, Bartosz, Filip Machaj, Jakub Rosik, & Andrzej Pawlik. (2019). Umbilical cord blood transplantation and the impact of the CTLA4 genotype on outcomes. Expert Review of Hematology. 12(12). 1089–1094. 1 indexed citations

20.

Szostak, Bartosz, Filip Machaj, Jakub Rosik, & Andrzej Pawlik. (2018). CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy. Expert Opinion on Investigational Drugs. 28(2). 149–159. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact